Parallel distribution: distribution of a centrally authorised product across Member States
Parallel distribution is resale of a centrally authorised medicine from one Member State in another, notified to EMA, which checks the pack and leaflet.
Parallel distribution is the centralised-procedure counterpart of parallel import. Because a centrally authorised product has a single authorisation valid across the EU, no new national licence is needed to move it between Member States. Instead, Article 57(1)(o) of Regulation (EC) No 726/2004 gives EMA the task of checking that distributors comply with the conditions laid down in EU law and in the marketing authorisation. The distributor notifies EMA of each product and the Member State of origin and destination, pays a fee, and EMA issues a parallel distribution notice once it has confirmed that the repackaged or relabelled presentation matches the approved product information in the destination language.
The distributor needs a wholesale distribution authorisation and, where it opens the pack or replaces the outer carton, a manufacturing authorisation, because relabelling and repackaging count as manufacturing. It must notify the marketing authorisation holder of its intention to distribute, as Article 76(4) of Directive 2001/83/EC requires, and it must decommission the original unique identifier and apply an equivalent one under the Falsified Medicines Directive. After the initial notice, EMA expects the distributor to keep its presentations in line with later variations, which is handled through notifications of change and periodic updates to EMA.
For the holder, parallel distribution is lawful competition with its own product, and the main interactions are the repackaging notices, trademark questions and the alignment of the parallel-distributed leaflet with the latest approved text. EMA publishes the list of parallel distribution notices, which gives holders a view of which presentations are being moved between markets, and the register is worth checking before a launch or a pack change in any market with a large price differential.
What goes wrong: distributors whose packs still carry the previous leaflet months after a safety variation, notices that cover a presentation the holder has since withdrawn, and holders who are surprised by a parallel-distributed pack in a market where they had planned a controlled launch. Both sides are also caught by the safety features rules, since a failure in decommissioning or in the new unique identifier generates alerts in the national verification system.
Timing
EMA checks each parallel distribution notification against the approved product information and issues the notice once the presentation is compliant, with clock-stops while the distributor corrects the mock-ups. After a variation to the centrally authorised product, the distributor must update its presentations and notify EMA, and EMA runs an annual update cycle for notices that are still in use. Distribution may not begin before the notice is issued.
Used in
Brand and regulatory teams watch EMA's parallel distribution notices for your products with Alerts.
Related terms
- Parallel import: import of a nationally authorised product from another Member StateParallel import is trade of a nationally authorised medicine from one EU Member State to another, outside the holder's channel, under a simplified licence.
- Centralised procedure: single EU marketing authorisation via EMAThe centralised procedure grants one marketing authorisation valid across the EU and EEA after a single EMA assessment and a Commission decision.
- Unique identifier: serialised code on prescription medicine packsThe unique identifier is the serialised 2D code on a prescription medicine pack that pharmacies verify against the EU repository before supply.
- Decommissioning: marking a unique identifier as suppliedDecommissioning changes a pack's unique identifier status in the EU verification system to inactive, normally when the pack is supplied to the public.
- Package leaflet: patient information leaflet in the packThe package leaflet is the patient-facing text in every medicine pack, required by Articles 58 and 59 of Directive 2001/83/EC and based on the SmPC.
Last updated